Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 1056-1060

  Fanciulli, Alessandra ^a,b   Misasi, Roberta ^c   Campanelli, Dario ^b   Buttarelli, Francesca R ^b   Pontieri, Francesco E ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine transporter; Levodopa; Parkinson's disease; Peripheral blood lymphocytes; Pramipexole; Ropinirole

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; PRAMIPEXOLE; ROPINIROLE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; IN VIVO STUDY; LONG TERM EXPOSURE; MALE; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

EID: 80053377770     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70622-3     Document Type: Article

References (22)

1. Barili P, Bronzetti E, Felici L, Ferrante F, Ricci A, Zaccheo D, Amenta F: Age-dependent changes in the expression of dopamine receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol, 1996, 71, 42-50.
2. Buttarelli FR, Capriotti G, Pellicano C, Prosperi D, Circella A, Festa A, Giovannelli M et al.: Central and peripheral dopamine transporter reduction in Parkinson's disease. Neurol Res, 2009, 31, 687-691.
3. Buttarelli FR, Fanciulli A, Pellicano C, Pontieri FE: The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders. Curr Neuropharmacol, 2011, 9, 278-288.
4. Caronti B, Antonini G, Calderaro C, Ruggieri S, Palladini G, Pontieri FE, Colosimo C: Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm, 2001, 108, 803-807. (Pubitemid 32694403)
5. Fahn S, Elton R, Members of the UPDRS development committee: The unified Parkinson's disease rating scale. In: Recent developments in Parkinson's disease. Eds. Fahn S, Marsden CD, Calne DB, Goldstein M. Vol. 2. Florham Park, NJ: Macmillan Health Care Informations, 1987, pp. 153-163, 293-304.
6. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson's disease. Arch Neurol, 1999, 56, 33-39.
7. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P: Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm, 2003, 100, 1119-1127. (Pubitemid 37271855)
8. Giros B, El Mestikawi S, Bertrand L, Caron MG: Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett, 1991, 295, 149-154.
9. Guttman M, Steward D, Hussey D, Wilson A, Houle S, Kish S: Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology, 2001, 56, 1559-1564. (Pubitemid 32544560)
10. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology, 1967, 17, 427-442.
11. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP et al.: Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society - European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol, 2006, 13, 1170-1185. (Pubitemid 44581464)
12. Jankovic J: Progression of Parkinson's disease: are we making progress in charting the course? Arch Neurol, 2005, 62, 351-352.
13. 3 receptor. BMC Biol, 2004, 2, 1-12.
14. 3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun, 1993, 194, 368-374.
15. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA, 2002, 287, 1653-1661.
16. Parkinson Study Group: Levodopa and the progression of Parkinson's disease. New Eng J Med, 2005, 351, 2498-2508.
17. Pellicano C, Buttarelli FR, Circella A, Tiple D, Giovannelli M, Benincasa D, Colosimo C et al.: Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. J Neural Transm, 2007, 114, 935-938. (Pubitemid 47013591)
18. 3H]7-OH-DPAT. J Neuroimmunol, 1995, 58, 139-144.
19. 123I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging, 2005, 32, 1452-1456.
20. Sossi V, Dinelle K, Schulzer M, Mak E, Doudet DJ, De La Fuente-Fernandez R: Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging, 2010, 37, 2364-2370.
21. Thrash T, Thiruchelvan K, Ahuja M, Suppiramaniam V, Dhanasekaran M: Methamphetamine - induced neurotoxicity: the road to Parkinson's disease. Pharmacol Rep, 2009, 61, 966-977.
22. 123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord, 2007, 22, 2346-2351.